Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Packer

Showing results (621-630 of 706) with videos related to

Pageof 71
Sort By:
Neuro-Oncology|April 5, 2012
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysisMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
The New England Journal of Medicine|September 21, 2023
Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 MutationsEric Bouffet, Jordan R Hansford, Maria Luisa Garrè, et al.
Pediatric Neurosurgery|January 1, 1996
Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group StudyM Deutsch, P R Thomas, J Krischer, et al.
Cancer|October 10, 2013
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022)Jason Fangusaro, Sridharan Gururangan, Tina Young Poussaint, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III studyP M Zeltzer, J M Boyett, J L Finlay, et al.
Neuro-Oncology|December 7, 2013
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium studySridharan Gururangan, Jason Fangusaro, Tina Young Poussaint, et al.
Neuro-Oncology|February 15, 2020
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conferenceRoger J Packer, Antonio Iavarone, David T W Jones, et al.
Journal of Medicinal Chemistry|May 21, 2024
Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Peter Barton, Erin Braybrooke, et al.
Developmental Cell|August 24, 2021
Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitorsEmmanuelle S Jecrois, Wang Zheng, Miriam Bornhorst, et al.
Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.
Pageof 71

Showing results (621-630 of 706) with videos related to

Sort By:
Pageof 71
Neuro-Oncology|April 5, 2012
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysisMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
The New England Journal of Medicine|September 21, 2023
Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 MutationsEric Bouffet, Jordan R Hansford, Maria Luisa Garrè, et al.
Pediatric Neurosurgery|January 1, 1996
Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group StudyM Deutsch, P R Thomas, J Krischer, et al.
Cancer|October 10, 2013
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022)Jason Fangusaro, Sridharan Gururangan, Tina Young Poussaint, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III studyP M Zeltzer, J M Boyett, J L Finlay, et al.
Neuro-Oncology|December 7, 2013
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium studySridharan Gururangan, Jason Fangusaro, Tina Young Poussaint, et al.
Neuro-Oncology|February 15, 2020
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conferenceRoger J Packer, Antonio Iavarone, David T W Jones, et al.
Journal of Medicinal Chemistry|May 21, 2024
Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Peter Barton, Erin Braybrooke, et al.
Developmental Cell|August 24, 2021
Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitorsEmmanuelle S Jecrois, Wang Zheng, Miriam Bornhorst, et al.
Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.
Pageof 71